Edward White sees positive road ahead after SPPI’s compelling cancer asset hits ORR of 73% in Exon 20.
Spectrum Pharmaceuticals, Inc.(NASDAQ:SPPI) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 50% upturn.
In a research report released Monday, H.C.
In a research report published Friday, H.C.
In a research note issued today, H.C.
In a research report sent to investors today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Spectrum Pharmaceuticals (NASDAQ:SPPI) with a …
In a research report issued Friday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Spectrum Pharmaceuticals (NASDAQ:SPPI) with a $15 price target, following …
In a research report issued today, H.C.